Adam Barsouk, P.R., K.S., Alexander Barsouk, J.S.A.
8 min
Melanoma is a significant and increasing public health challenge, representing the fifth most common cancer in the United States. Although it accounts for only a small percentage of total skin cancers, it is responsible for the vast majority of skin cancer-related mortality. The authors provide an epidemiological overview of the disease, exploring its rising incidence, mortality trends, and the multifaceted nature of its risk factors.
The incidence of melanoma has surged by over 320% in the United States since 1975, a trend mirrored in many other developed, fair-skinned populations. While the rise in cases is concerning, mortality rates have followed a different trajectory. After years of increasing, US melanoma mortality dropped by nearly 18% between 2013 and 2016. This shift is primarily attributed to the approval of ten new targeted and immunotherapy agents since 2011, which have revolutionized care for patients with advanced, stage IV disease.
Ultraviolet (UV) radiation remains the primary environmental driver of melanoma. The study highlights that UV-induced DNA damage, specifically in the absence of effective repair mechanisms, triggers oncogenic mutations in pathways like BRAF and NRAS. Beyond solar exposure, indoor tanning, immunosuppression, family history, and genetic predispositions are identified as key drivers.
Public health education is emphasized as a critical tool. The success of Australia's SunSmart program, which contributed to a peak and subsequent decline in melanoma incidence by prioritizing sun-protective behaviors and shade-seeking, serves as a model. Conversely, the US currently faces a gap in primary prevention, with fewer than 40% of Americans reporting the use of adequate sun protection. The authors argue that increased investment in education and targeted screening for high-risk individuals—such as older, fair-skinned men—offers a high return on investment and potential for further reducing mortality.
Melanoma accounts for 1.7% of global cancer diagnoses and is the fifth most common cancer in the US. Melanoma incidence is rising in developed, predominantly fair-skinned countries, growing over 320% in the US since 1975. However, US mortality has fallen almost 30% over the past decade with the approval of 10 new targeted or immunotherapy agents since 2011. Mutations in the signaling-protein BRAF, present in half of cases, are targeted with oral BRAF/MEK inhibitor combinations, while checkpoint inhibitors are used to restore immunosurveillance likely inactivated by UV radiation. Although the overall 5-year survival has risen to 93.3% in the US, survival for stage IV disease remains only 29.8%. Melanoma is most common in white, older men, with an average age of diagnosis of 65. Outdoor UV exposure without protection is the main risk factor, although indoor tanning beds, immunosuppression, family history and rare congenital diseases, moles, and obesity contribute to the disease. Primary prevention initiatives in Australia implemented since 1988, such as education on sun-protection, have increased sun-screen usage and curbed melanoma incidence, which peaked in Australia in 2005. In the US, melanoma incidence is not projected to peak until 2022-2026. Fewer than 40% of Americans report practicing adequate protection (sun avoidance from 10 a.m.-4 p.m. and regular application of broad-spectrum sunscreen with an SPF > 30). A 2-4-fold return on investment is predicted for a US sun-protection education initiative. Lesion-directed skin screening programs, especially for those at risk, have also cost-efficiently reduced melanoma mortality.
Sam: The review describes treatments aimed at each. BRAF is a signaling protein altered in many melanomas; combinations targeting that pathway can interrupt growth signals. Checkpoint inhibitors help immune cells recognize and attack cancer, rather than targeting the tumor’s growth machinery directly.
Alex: That mechanism sounds compelling, but an overall survival statistic could hide patients who still do badly. How uneven is the progress?
Sam: The review reports overall five-year survival of about ninety-three percent in the United States. Most patients in those data were diagnosed before regional or distant spread. For disease already spread to distant sites at diagnosis, five-year survival was only about thirty percent.
Alex: So the overall figure shouldn’t reassure us about advanced disease. It also makes the timing of diagnosis central to interpreting survival.
Sam: Yes, but it doesn’t by itself establish that population screening reduces deaths. Outcomes differ sharply by stage at diagnosis. Whether a screening program improves outcomes requires separate evidence, which we’ll come back to.
Alex: First, who is carrying the risk? If the review mostly describes fair-skinned populations, we shouldn’t generalize every conclusion.
Sam: US incidence is highest among white men, and diagnoses cluster in older adults. But melanoma is not confined to that group. The review describes acral lentiginous melanoma, arising on palms, soles, and nailbeds, as more likely among darker-skinned ethnicities.
Alex: Does that also limit the sunlight explanation? Not every melanoma begins on sun-exposed skin.
Sam: It does. The review identifies ultraviolet exposure as the primary risk factor for melanoma of the skin. It also describes rarer melanomas in mucosal tissue or the eye that are likely independent of sun exposure. The prevention argument needs that boundary.
Alex: Beyond sunlight, which risks matter most for interpreting the review, rather than simply collecting a long list?
Sam: Indoor tanning is a major preventable exposure, with risk increasing alongside greater use. Suppressed immunity, family history, and having many moles also matter. Moles can be both potential precursors and markers of increased risk, although any individual mole rarely transforms.
Alex: That separates modifiable exposure from people who may need closer observation. What evidence makes the education argument more than sensible advice?
Sam: There are separate strands. The review cites randomized trials in which regular sunscreen use reduced melanoma rates decades later. For public education programs, it draws heavily on Australia, where campaigns combined messages with school policies and protective behavior.
Alex: What did that look like in practice? An actual intervention helps distinguish a prevention program from simply telling people to be careful.
Sam: Victoria’s SunSmart program used television advertising to encourage hats and sunscreen. Its school accreditation program required hats, shade seeking, and adults modeling protective behavior. The intervention extended into daily settings, rather than relying only on individual knowledge.
Alex: And what changed after that? Behavior, sunburn, and melanoma incidence aren’t interchangeable outcomes.
Sam: A synthesis of cross-sectional studies found that sunburn incidence had halved. The review also reports greater sun protection and a later peak in Australian melanoma incidence. Those observations support the prevention argument, but they don’t isolate the campaign’s causal effect.
Alex: So the sunscreen trials support a protective intervention, while the Australian experience shows a broader implementation model. The strength of inference differs.
Sam: That distinction is essential. The authors recommend Australia as a model for the United States, where reported protection remains low. But the campaign evaluations are not a randomized national comparison, and the US incidence peak discussed here was projected, not observed.
Alex: Now back to screening. If earlier-stage patients fare better, what stops the review from recommending examinations for every asymptomatic adult?
Sam: It reports that the US Preventive Services Task Force found insufficient evidence for that broad population. The authors nevertheless recommend regular screening for people with elevated risk, including relevant family history, genetic predisposition, or substantial sun exposure and fair skin.
Alex: Does it offer a less resource-intensive approach for those settings, or only recommend more examinations?
Sam: It describes a Belgian study comparing lesion-directed examinations with whole-body examinations. Detection rates were similar, while whole-body examinations took substantially longer. That supports a possible efficiency advantage in that study, not proof of equivalent mortality benefits.
Alex: Across all these sources, what most limits how confidently we should use the review?
Sam: It combines registries, trials, observational studies, and models, covering different places and periods. It doesn’t present a systematic search protocol or a formal assessment of bias. I’d use it as an orientation to the evidence, not a definitive ranking of interventions.
Alex: For someone deciding whether to read it fully, where does that leave the verdict?
Sam: Researchers in cancer prevention and screening should start with Primary Prevention and Education, then Screening. Compare the trial evidence with the program evaluations and the uncertainty around broad screening. For clinical context, read Survival, especially the contrast between early and distant disease. Everyone else should remember: fewer deaths do not mean prevention is finished.
Alex: Thanks for listening.